Why a biotech firm's market value jumped from $3M to $130M in a day and is still way up from its 'almost unfathomably low valuation'

Results from a Roche-Run liver cancer trial involving Tempest Therapeutics' experimental therapy sent its shares surging.

  Travel   Oct 13, 2023   0  Add to Reading List
Why a biotech firm's market value jumped from $3M to $130M in a day and is still way up from its 'almost unfathomably low valuation'
Results from a Roche-Run liver cancer trial involving Tempest Therapeutics' experimental therapy sent its shares surging. Read More
Read More